ClinVar Miner

Submissions for variant NM_000171.4(GLRA1):c.947C>A (p.Ala316Glu)

dbSNP: rs1064795797
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000486352 SCV000571947 likely pathogenic not provided 2016-10-17 criteria provided, single submitter clinical testing The A316E variant in the GLRA1 gene has not been reported previously as a pathogenic variant nor as abenign variant, to our knowledge. The A316E variant was not observed in approximately 6500 individuals ofEuropean and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a commonbenign variant in these populations. The A316E variant is a non-conservative amino acid substitution, which islikely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties.This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant isprobably damaging to the protein structure/function. Missense variants in a nearby residue, L319P, has been reportedin the Human Gene Mutation Database in association with hyperekplexia (Stenson et al., 2014), supporting thefunctional importance of this region of the protein. The A316E variant is a strong candidate for a pathogenic variant.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.